| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 8-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Hospital Division | 51.6 | 49.3 | 46.5 | 21.2 | 51.6 | 79.1 | | 118.0 |
| Population Health Management Division | 7.3 | 7.0 | 7.2 | 7.2 | 6.4 | | | |
| Other | | | | 0.6 | | | | |
| Total revenues | 58.9 | 56.3 | 53.7 | 29.0 | 58.0 | 1.5 | 5.9 | 118.0 |
| Revenue growth [+] | 1.5% | 3638.7% | 807.5% | -75.4% | -7.6% | -25.2% | 1411.4% | 33603.1% |
| Hospital Division | 0.0% | -37.7% | | -82.0% | -17.8% | | | |
| Population Health Management Division | 13.5% | | | | | | | |
| Cost of goods sold | 24.9 | 9.4 | 35.0 | 55.5 | 24.4 | 34.3 | 4.5 | 20.0 |
| Gross profit | 34.1 | 47.0 | 18.7 | -26.5 | 33.7 | -32.8 | 1.4 | 97.9 |
| Gross margin | 57.8% | 83.4% | 34.8% | -91.3% | 58.0% | -2177.2% | 24.1% | 83.0% |
| Selling, general and administrative [+] | 13.0 | 11.2 | 6.3 | 10.1 | 6.7 | 10.8 | 4.2 | 9.5 |
| General and administrative [+] | 13.0 | 11.2 | 6.3 | 10.1 | 6.7 | 10.8 | 4.2 | 9.5 |
| General and administrative expenses | 9.8 | 7.2 | 6.3 | 4.1 | 4.1 | 6.6 | 4.2 | 1.5 |
| Insurance expense | | | | 3.5 | | | | 3.1 |
| Research and development | | | | | | | 0.1 | |
| Other operating expenses | 17.2 | 36.2 | 14.9 | -10.3 | 21.4 | -75.3 | 0.2 | 12.1 |
| EBITDA [+] | 3.8 | -0.5 | -2.5 | -26.2 | 5.6 | 31.6 | -2.9 | 76.3 |
| EBITDA growth | -32.5% | -101.4% | -12.5% | -134.3% | -79.7% | -874.5% | -181.3% | 4141.0% |
| EBITDA margin | 6.5% | -0.8% | -4.7% | -90.4% | 9.7% | 2099.7% | -48.4% | 64.7% |
| Depreciation | 3.8 | 3.6 | 3.3 | 4.3 | 2.7 | 2.4 | 0.0 | 1.9 |
| EBITA | 0.1 | -4.1 | -5.8 | -30.5 | 2.9 | 29.2 | -2.9 | 74.5 |
| EBITA margin | 0.1% | -7.2% | -10.8% | -105.3% | 5.0% | 1940.7% | -48.4% | 63.1% |
| Amortization of intangibles | 0.4 | 0.4 | | | 0.4 | | 0.2 | 0.0 |
| EBIT [+] | -0.4 | -4.4 | -5.8 | -30.5 | 2.5 | 29.2 | -3.1 | 74.5 |
| EBIT growth | -114.5% | -115.2% | 86.0% | -141.0% | -90.9% | -804.6% | -188.2% | 4096.5% |
| EBIT margin | -0.6% | -7.9% | -10.8% | -105.3% | 4.3% | 1940.7% | -52.5% | 63.1% |
| Non-recurring items [+] | | | | 408.5 | 3.9 | | | |
| Asset impairment | | | | 408.5 | | | | |
| Interest expense, net [+] | 4.8 | 3.1 | 2.9 | 3.4 | 4.4 | 1.9 | 1.3 | 1.3 |
| Interest expense | 4.8 | 3.1 | 2.9 | 3.4 | 4.4 | 1.9 | 1.3 | 1.3 |
| Interest income | | | | | | | 0.0 | |
| Other income (expense), net [+] | 0.1 | -0.2 | -0.2 | 0.6 | 1.4 | -2.4 | -1.2 | 1.7 |
| Other | 0.1 | -0.2 | 0.2 | 0.6 | 1.4 | -2.4 | -2.5 | 1.7 |
| Pre-tax income | -5.1 | -7.8 | -8.9 | -441.8 | -4.3 | 25.0 | -5.6 | 74.9 |
| Income taxes | -0.8 | -0.9 | 1.8 | -8.5 | 19.7 | 0.2 | 1.0 | 0.5 |
| Tax rate | 16.0% | 11.6% | | 1.9% | | 0.7% | | 0.6% |
| Minority interest | -0.8 | -1.8 | 4.1 | -10.7 | -4.7 | 3.4 | 0.0 | 20.7 |
| Net income | -3.5 | -5.1 | -14.8 | -422.5 | -19.3 | 21.4 | -4.6 | 53.8 |
| Net margin | -5.9% | -9.1% | -27.5% | -1457.0% | -33.2% | 1423.2% | -77.4% | 45.6% |
| |
| Basic EPS [+] | ($0.01) | ($0.01) | ($0.02) | ($0.65) | ($0.03) | $0.04 | ($0.12) | $0.09 |
| Growth | -82.2% | -121.9% | -83.9% | -816.8% | -165.4% | -115.1% | -90.6% | -73.2% |
| Diluted EPS [+] | ($0.01) | ($0.01) | ($0.02) | ($0.65) | ($0.03) | $0.04 | ($0.12) | $0.09 |
| Growth | -82.2% | -121.9% | -83.9% | -811.1% | -165.4% | -115.1% | -90.6% | -73.2% |
| |
| Shares outstanding (basic) [+] | 656.6 | 650.9 | 737.6 | 649.6 | 646.4 | 592.8 | 36.9 | 592.8 |
| Growth | 1.6% | 9.8% | 1896.5% | 9.6% | 9.0% | 3092.0% | 645.4% | 11345.3% |
| Shares outstanding (diluted) [+] | 656.6 | 650.9 | 737.6 | 654.8 | 646.4 | 592.8 | 36.9 | 592.8 |
| Growth | 1.6% | 9.8% | 1896.5% | 10.5% | 9.0% | 3092.0% | 645.4% | 11345.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |